Depletion of excessive liver iron stores with desferrioxamine.
To determine the therapeutic effect of long-term, intensive iron chelation therapy, we studied liver iron content and histology in four children with thalassaemia major during 52-83 months of intensive therapy with desferrioxamine. The initial biopsies obtained prior to or within 21 months after beginning chelation therapy had Grade IV iron staining, with heavy iron deposition present in parenchymal and reticuloendothelial cells. Subsequent biopsies, obtained when serum ferritin levels had fallen to 71-246 micrograms/l, contained Grade 0 or Grade I stainable iron. Little or no iron was present in parenchymal or reticuloendothelial cells. The liver iron concentration, measured by magnetic susceptibility, returned to normal or nearly normal levels. Hepatic fibrosis did not progress during treatment with desferrioxamine. These findings demonstrate that intensive and sustained chelation therapy with desferrioxamine will remove excessive liver iron and preserve hepatocellular structure.
D000293:Adolescent; D002648:Child; D003676:Deferoxamine / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000032:analysis*; D008099:Liver / Q000032:analysis*; D013789:Thalassemia / Q000188:drug therapy* / Q000378:metabolism
D007501:Iron; D003676:Deferoxamine